Stalevo Articles
US FDA questions safety of Novartis/Orion’s Stalevo due to possible increased cardiovascular risk
23 August 2010
Orion withdraws MAA for expanded Stalevo label
16 March 2009
Orion files suit blocking Wockhardt's generic Stalevo
26 January 2009
Wockhardt seeks to make generic of Orion's Stalevo in USA
15 December 2008
FDA clears two new strengths of Novartis' Stalevo
3 November 2008
Orion seek broader indication for Stalevo
21 April 2008
Orion/Novartis' Stalevo fares well in Ph III trial
4 February 2008
Higher dose of Novartis' Stalveo cleared in USA
13 August 2007
CORRECTION: Novartis' Stalevo
13 August 2007
Orion Pharma sees 37% hike in 2005 profits
20 February 2006
Australian PBS new Rx listings aimed at seniors
11 April 2005
Orion sees sales fall for first nine months
15 November 2004
Trial to assess Stalevo in delaying dyskinesia
13 September 2004
Orion/Abbott expand levosimendan accord
26 April 2004
Orion's Stalevo available in the UK
22 December 2003
EU clears Orion/Novartis' Stalevo
3 November 2003
Orion and Novartis' Stalevo shows benefits in Parkinson's disease
8 September 2003
Orion's PD therapy is approved by FDA
30 June 2003
Showing 1-20 of 20 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
